Fundraising FoxDuke Capital Partners — 2023 Investments
4 investments dated 2023 · listed companies and verified rows first · show all
Liquid AI builds device-native foundation models (LFMs) designed to run efficiently on processors outside data centers, such as phones, laptops, and cars, under latency, privacy, and hardware constraints.
AI & Machine LearningDeep TechEnterprise SoftwareBrookline, US
Daniela Rus(Founder)inMathias Lechner(Founder)inRamin Hasani(Founder)inAlexander Amini(Founder)inLouis Hunt(Executive Officer)Stephen Pagliuca(Director)
Co-investorsBold Capital PartnersGlasswing VenturesIsaiISAI GestionLink VenturesOSS Capital+6 more
Pryon provides a memory layer platform that helps enterprises move AI projects into production by ingesting, governing, and securing content across multiple formats and sources.
AI & Machine LearningData & InfrastructureDeveloper ToolsEnterprise SoftwareSaaSRaleigh, US
JD Vance(Director)Igor Jablokov(Founder)
Co-investors7BC Venture CapitalAperture Venture CapitalCrosscourt VenturesGaingelsGood Growth CapitalGreycroft+11 more
__Twitter.png)
Reselute is a privately held medical device company developing orthopedic implant systems that combine structural fixation with controlled local drug delivery.
BiotechHealthtechMedical DevicesDurham, US
Cambre Kelly(President and CEO)inKen Gall(Director)
BoardAndrew Beaver(Director)
Co-investorsBand of AngelsCharlotte Angel Fund
Tune Therapeutics develops a therapeutic platform targeting the epigenome to treat complex diseases and regenerative medicine applications.
BiotechDeep TechHealthtechLongevityMedical DevicesDurham and Seattle, US
Akira Matsuno(Co-Founder, President, CFO, COO)inDerek Jantz(Executive Officer)inCharles Gersbach(Co-Founder)inJohn McHutchison(CEO, Chairman of the Board)inDan McHugh(Co-Founder, Investor)inBlythe Sather(Executive Officer)in
Co-investorsHatteras Venture PartnersMission BiocapitalNew Enterprise Associates (NEA)Pappas CapitalRV Invest GmbHSaisei Ventures+2 more
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.